allogenic hepatocyte-like mesenchymal stem cells

Allogenic hepatocyte-like mesenchymal stem cells are an experimental cell therapy developed by Cairo University for the treatment of Hemophilia A. The therapeutic approach involves isolating mesenchymal stem cells (MSCs) from the bone marrow of healthy donors and inducing them in vitro to differentiate into a hepatocyte-like phenotype. These differentiated cells are characterized by their ability to synthesize albumin and, most importantly, Coagulation factor VIII (FVIII). The cells are then transplanted into the patient via the portal vein (often through a splenic approach) to provide a functional source of FVIII, aiming to convert severe hemophilia into a milder form by partially replacing mutant liver cells with healthy, factor-producing cells.

Other names

allogenic bone marrow-derived mesenchymal stem cellshepatocyte-like cellsFVIII-producing hepatocyte-like cellsallogenic hepatocyte-induced bone marrow mesenchymal stem cells